Charles D. Pauza - 12 Dec 2025 Form 4 Insider Report for Traws Pharma, Inc. (TRAW)

Reporting relationship: Chief Science Officer Virology
Issuer ticker: TRAW
Reported as of: 12 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Dec 2025, 18:16:22 UTC
Prior SEC filing: 15 Oct 2025
Next SEC filing: 10 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Charles David Pauza

Key filing fact

Charles D. Pauza filed Form 4 for Traws Pharma, Inc. (TRAW) on 16 Dec 2025.

Key facts

This page summarizes Charles D. Pauza's Form 4 filing for Traws Pharma, Inc. (TRAW).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Dec 2025, 18:16.

Change

Previous filing in this sequence was filed on 15 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002018150 Primary reporting owner

Pauza Charles David

Relationship: Chief Science Officer Virology
Address: C/O TRAWS PHARMA, INC., 12 PENNS TRAIL, NEWTOWN
Signature: /s/ Charles David Pauza
Signature date: 16 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TRAW transaction

Common Stock

Award

Transaction value: $0
Shares: +18,471
Change %: +19%
Price: $0.000000
Shares after: 115,971
Date: 12 Dec 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRAW transaction Derivative

Stock Option (right to purchase)

Award

Transaction value: $0
Shares: +73,886
Change %
Price: $0.000000
Shares after: 73,886
Date: 12 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 73,886
Exercise price: $2.33
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

Footnote F2

The options vest 100% on the first anniversary of the grant date.